Market focus Target autoimmune diseases including type 1 diabetes and cancer with Century’s allogeneic iPSC-derived therapies.Sales opportunities exist with large pharma and biotech partners seeking off-the-shelf, scalable cell therapies and collaborations around autoimmune and oncologic indications.

Expansion signals Active outreach at major conferences (ADA Scientific Sessions, Piper Sandler Healthcare Conference, Chardan Genetic Medicines Conference) indicates readiness for partnerships, licensing deals, and research collaborations to accelerate clinical programs.

Technical moat Integrated platform combining gene editing, protein engineering, and manufacturing for allogeneic iPSC-derived therapies suggests opportunities to sell or co-develop process development, GMP manufacturing capacity, and analytical services to support scale-up and regulatory readiness.

Funding and growth IPO-backed funding and ongoing investor activity imply capacity for strategic collaborations, joint ventures, or milestone-based deals, particularly with teams seeking to leverage Century’s technology for autoimmune or cancer indications.

Competitive positioning Compared to peers, Century’s focus on iPSC-derived allogeneic therapies with a broad autoimmune and cancer target pipeline positions it for partnerships that require rapid therapeutic development, off-the-shelf timelines, and access to experienced CSO-led scientific leadership.